257 results on '"Cataland S"'
Search Results
2. OC 14.1 Phase 3 Prospective, Randomized, Controlled, Open-Label, Multicenter, Crossover Study of Recombinant ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura
3. OC 14.2 Pharmacokinetic Characteristics of ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Results from a Phase 3 Randomized, Controlled, Open-Label, Crossover Study
4. OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis from Phase 3B Continuation Study
5. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
6. Prolonged platelet storage associated with increased frequency of transfusion‐related adverse events
7. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy
8. S294: LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST-HERCULES STUDY
9. Caplacizumab in acquired thrombotic thrombocytopenic Purpura (aTTP): Long-term Safety and Efficacy in the Post-HERCULES Study
10. Timely formation of ULVWF multimers and reduction of ADAMTS13 activity precede clinical events of TTP relapse: OR362
11. Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use
12. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis
13. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
14. Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry
15. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
16. OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL
17. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura
18. Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
19. Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study
20. S100β as a Sensitive Biomarker for Acute and Chronic Neurologic Injury in TTP Patients: SP58
21. Title: objective documentation of neurologic injury in patients with idiopathic thrombotic thrombocytopenic purpura (TTP): OC-WE-129
22. Longitudinal performances of ADAMTS13 antigen and activity over the course of idiopathic TTP: OC-WE-130
23. ADAMTS13 activity, race, and age as predictors of exacerbation in patients with idiopathic TTP: OC-WE-009
24. Cyclosporine Is Effective Prophylactic Therapy in Preventing Recurrences of TTP: *SP23
25. Low ADAMTS13 Activity in Clinical Remission Predicts the Risk of TTP Relapses: S32–030G
26. Full evaluation of an acquired case of thrombotic thrombocytopenic purpura following the surgical resection of glioblastoma multiforme
27. An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura
28. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry
29. Résultats d’efficacité d’une analyse intégrée des essais cliniques de phase 2 et 3 évaluant caplacizumab dans le purpura thrombotique thrombocytopénique acquis
30. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
31. Résultats de l’essai de phase III HERCULES – Essai contrôlé randomisé en double aveugle du caplacizumab dans le traitement du purpura thrombotique thrombocytopénique acquis
32. Prolonged platelet storage associated with increased frequency of transfusion-related adverse events
33. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
34. Risk Factors and Manageability of the Mucocutaneous Bleeding Profile Observed in aTTP Patients Treated with Caplacizumab during the Phase III HERCULES Study.
35. Safety Results Normalized to Time of Exposure during the Phase 3 HERCULES Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura.
36. Pancreatic polypeptide in acute pancreatitis and small-bowel infarction in dogs
37. Effects of pancreatic polypeptide and vasoactive intestinal polypeptide on rat ileal and colonic water and electrolyte transportin vivo
38. Advances in Understanding and Treatment of Thrombotic Thrombocytopenia Purpura
39. LIST OF CONTRIBUTORS AND DISCUSSANTS
40. Pathology of Gastric Inhibitory Polypeptide
41. ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome
42. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura
43. A single center review of the experience with mitomycin C (MMC) and the risk of thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS)
44. Somatostatin decreases diarrhea in patients with the short-bowel syndrome.
45. Identification of tissue insulin receptors: use of a unique in vivo radioreceptor assay.
46. Theoretical basis for a new in vivo radioreceptor assay for polypeptide hormones.
47. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy.
48. Exercise adaptation responses for gastric inhibitory polypeptide (GIP) and insulin in obese children. Possible extra-pancreatic effects.
49. Production of 12-hydroxyeicosatetraenoic acid and vitamin E status in platelets from type I human diabetic subjects.
50. THE EFFECT OF INCREASING DOSES OF INGESTED GLUCOSE ON INSULIN AND GASTRIC INHIBITORY POLYPEPTIDE (GIP) CONCENTRATIONS IN MAN.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.